文献速递中医内科中药与中成药合理使用中医康复

中药靶向翻译后修饰治疗脑缺血再灌注损伤的研究进展

Targeting post-translational modifications by traditional Chinese medicine in cerebral ischemia-reperfusion injury: Recent advances.
PubMed 文献 · J Ethnopharmacol · 2026-06-24

该综述系统检索了2015至2025年间PubMed、Web of Science、CNKI和万方等数据库中关于卒中、脑缺血再灌注损伤(CIRI)及翻译后修饰(PTMs)的文献,探讨中药复方、活性成分和特色中医疗法如何通过调控磷酸化、乙酰化、泛素化和乳酸化等PTMs发挥对CIRI的防治作用,并指出PTMs是CIRI治疗的关键靶点,但下游靶点及具体调控位点仍需进一步研究。

要点

  • 中药复方、单味药及单体成分可通过调控磷酸化、乙酰化、泛素化与乳酸化抑制CIRI进展。
  • PTMs是CIRI治疗的关键靶点,但中药调控PTMs的下游靶点及具体位点尚待阐明。
  • 临床应用需关注中药潜在不良反应并密切监测个体差异。

核心结论

  • PTMs是CIRI治疗的关键靶点,中药在对抗CIRI方面显示出疗效。
  • 需进一步探究中药调控PTMs的下游靶点及CIRI进程中PTMs的具体调控位点。
  • 应重视评估中药的潜在不良反应并密切监测临床应用的个体差异。

研究设计与样本

  • 综述系统检索PubMed、Web of Science、CNKI和万方数据库中2015至2025年发表的相关文献,检索词涉及卒中、CIRI、翻译后修饰、磷酸化、乙酰化、泛素化和乳酸化,药用植物学名经药用植物名称服务(MPNS)确认。

主要发现

  • 中药复方、单味药和单体化合物通过调控磷酸化、乙酰化、泛素化和乳酸化等PTMs,对CIRI的发生发展发挥抑制作用。

临床怎么用

  • 中药复方、活性成分及特色疗法可通过调控PTMs用于CIRI的防治,体现多成分、多靶点、宽谱调控及辨证论治的个体化治疗优势。
  • 临床应用中需关注中药潜在不良反应并密切监测个体差异。

局限性

  • 中药调控PTMs的下游靶点尚未充分探索,CIRI发生发展中PTMs的具体调控位点有待阐明。
  • CIRI后PTMs的复杂调控网络和治疗靶点的阐明仍是高度优先事项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Globally, ischemic stroke is a major contributor to global mortality. Cerebral ischemia-reperfusion injury (CIRI) occurs as a pathophysiological event subsequent to blood flow restoration, which accelerates the transmission of pathological signals and exacerbates damage. Current medical interventions still carry certain risks. Traditional Chinese medicine (TCM), characterized by its multi-component and multi-target nature, offers distinctive advantages including multi-constituent profiles, pleiotropic targeting capabilities, and broad-spectrum regulatory characteristics. In clinical practice, TCM enables individualized treatment based on syndrome differentiation and pharmacological regulation, forming a disease management chain encompassing prevention, treatment, and functional rehabilitation, thereby demonstrating significant promise in the treatment of CIRI. AIM OF THE STUDY: This review systematically examines how TCM formulas, active components, and characteristic TCM therapies regulate post-translational modifications (PTMs) to prevent and treat CIRI. The regulatory mechanisms involved include phosphorylation, acetylation, ubiquitination, and lactylation, thereby offering novel perspectives for treatment of CIRI. MATERIALS AND METHODS: Relevant literature was systematically retrieved from databases such as PubMed, Web of Science, CNKI, and Wanfang Database by employing search terms associated with stroke, CIRI, post-translational modifications, phosphorylation, acetylation, ubiquitination, and lactylation. The search covered relevant literature published between 2015 and 2025. The scientific names of medicinal plants were confirmed through the Medicinal Plant Names Services (MPNS, http://mpns.kew.org). RESULTS: By regulating PTMs, including phosphorylation, acetylation, ubiquitination, and lactylation, TCM formulas, individual herbs, and monomeric compounds exert suppressive effects on the development and progression of CIRI. CONCLUSION: PTMs represent key therapeutic targets in the treatment of CIRI. TCM demonstrates efficacy in counteracting CIRI. However, further exploration is needed to investigate the downstream targets of PTMs regulated by TCM and to elucidate the specific regulatory sites of PTMs during the development and progression of CIRI. Additionally, attention should be given to evaluating the potential adverse effects of TCM and closely monitoring individual variations in clinical application. Elucidating the complex regulatory networks and therapeutic targets of PTMs following CIRI remains a high priority.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Gu Y, Jiang L, Qi C, et al. Targeting post-translational modifications by traditional Chinese medicine in cerebral ischemia-reperfusion injury: Recent advances. J Ethnopharmacol. 2026. PMID: 42341852. doi:10.1016/j.jep.2026.122111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。